Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Pharvaris N.V. - Ordinary Shares (NQ:PHVS)

37.61 -0.23 (-0.61%)

Streaming Delayed Price Updated: 3:31 PM EDT, Sep 9, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,036,637
Open	38.26
Bid (Size)	37.56 (300)
Ask (Size)	37.66 (500)
Prev. Close	37.84
Today's Range	37.05 - 39.18
52wk Range	20.65 - 43.25
Shares Outstanding	33,816,459
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks

September 08, 2026

From Pharvaris N.V.

Via GlobeNewswire

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It ↗

September 06, 2026

Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.

Via MarketBeat

Performance

YTD	+42.0%	+42.0%
1 Month	+8.0%	+8.0%
3 Month	+19.0%	+19.0%
6 Month	+45.3%	+45.3%
1 Year	+72.3%	+72.3%

More News

Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026

September 03, 2026

From Pharvaris N.V.

Via GlobeNewswire

Pharvaris NV (NASDAQ:PHVS) Reports Q4 2025 Financial Results and Key Pipeline Milestones ↗

April 02, 2026

Via Chartmill

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

August 12, 2026

From Pharvaris N.V.

Via GlobeNewswire

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

August 06, 2026

From Pharvaris N.V.

Via GlobeNewswire

After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over? ↗

July 24, 2026

Via The Motley Fool

Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema

July 22, 2026

From Pharvaris N.V.

Via GlobeNewswire

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

July 06, 2026

From Pharvaris N.V.

Via GlobeNewswire

Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026

June 15, 2026

From Pharvaris N.V.

Via GlobeNewswire

Pharvaris Announces Annual General Meeting of Shareholders

June 11, 2026

From Pharvaris N.V.

Via GlobeNewswire

Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

May 29, 2026

From Pharvaris N.V.

Via GlobeNewswire

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗

May 19, 2026

Via The Motley Fool

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗

May 19, 2026

Via The Motley Fool

Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026

From Pharvaris N.V.

Via GlobeNewswire

Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000 ↗

May 11, 2026

Via The Motley Fool

Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

May 11, 2026

From Pharvaris N.V.

Via GlobeNewswire

Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares

May 08, 2026

From Pharvaris N.V.

Via GlobeNewswire

For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next ↗

April 29, 2026

Via The Motley Fool

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference

April 20, 2026

From Pharvaris N.V.

Via GlobeNewswire

Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors. ↗

April 13, 2026

Via The Motley Fool

Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

April 02, 2026

From Pharvaris N.V.

Via GlobeNewswire

Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology

March 20, 2026

From Pharvaris N.V.

Via GlobeNewswire

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗

March 18, 2026

Via The Motley Fool

Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗

March 18, 2026

Via The Motley Fool

Frequently Asked Questions

Is Pharvaris N.V. - Ordinary Shares publicly traded?

Yes, Pharvaris N.V. - Ordinary Shares is publicly traded.

What exchange does Pharvaris N.V. - Ordinary Shares trade on?

Pharvaris N.V. - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Pharvaris N.V. - Ordinary Shares?

The ticker symbol for Pharvaris N.V. - Ordinary Shares is PHVS on the Nasdaq Stock Market

What is the current price of Pharvaris N.V. - Ordinary Shares?

The current price of Pharvaris N.V. - Ordinary Shares is 37.61

When was Pharvaris N.V. - Ordinary Shares last traded?

The last trade of Pharvaris N.V. - Ordinary Shares was at 09/09/26 03:31 PM ET

What is the market capitalization of Pharvaris N.V. - Ordinary Shares?

The market capitalization of Pharvaris N.V. - Ordinary Shares is 1.27B

How many shares of Pharvaris N.V. - Ordinary Shares are outstanding?

Pharvaris N.V. - Ordinary Shares has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.